var data={"title":"Methimazole: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Methimazole: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6552?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=methimazole-drug-information\" class=\"drug drug_general\">see &quot;Methimazole: Drug information&quot;</a> and <a href=\"topic.htm?path=methimazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Methimazole: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520218\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tapazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194315\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dom-Methimazole;</li>\n      <li>PHL-Methimazole;</li>\n      <li>Tapazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060271\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antithyroid Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13766154\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Congenital Hyperthyroidism:</b> Oral: Initial: 0.25 to 1 mg/kg/day divided every 8 to 12 hours; if satisfactory therapeutic response not observed within 24 to 36 hours, consider 50% dose increase (Kliegman 2016; Sperling 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060265\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=methimazole-drug-information\" class=\"drug drug_general\">see &quot;Methimazole: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperthyroidism</b>: Infants, Children, and Adolescents: Oral: Initial: 0.4 mg/kg/<b>day</b> in 3 divided doses (approximately every 8 hours); maintenance 0.2 mg/kg/<b>day</b> in 3 divided doses (50% of initial)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Graves disease</b> (ATA [Ross 2016]): <b>Note</b>: In severe cases, higher doses may be required (50% to 100% higher); once patient euthyroid, reduce dose by &ge;50% to maintain euthyroid; duration of therapy usually 1 to 2 years</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-based dosing: Infants, Children, and Adolescents: Oral: Initial: 0.2 to 0.5 mg/kg/dose once daily (range: 0.1 to 1 mg/kg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing (using <sup>1</sup>/<sub>4</sub>, <sup>1</sup>/<sub>2</sub>, or whole tablets): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: 1.25 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 1 to 5 years: 2.5 to 5 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 5 to 10 years: 5 to 10 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;10 years and Adolescents: 10 to 20 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperthyroidism:</b> Oral: Initial: 15 mg/day in 3 divided doses (approximately every 8 hours) for mild hyperthyroidism; 30 to 40 mg/day in moderately severe hyperthyroidism; 60 mg/day in severe hyperthyroidism; maintenance: 5 to 15 mg/day (may be given as a single daily dose in many cases)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adjust dosage as required to achieve and maintain serum T<sub>3</sub>, T<sub>4</sub>, and TSH levels in the normal range. An elevated T<sub>3</sub> may be the sole indicator of inadequate treatment. An elevated TSH indicates excessive antithyroid treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Graves disease</b>\n      <b>:</b> Oral: Initial: 10 to 20 mg once daily to restore euthyroidism; maintenance: 5 to 10 mg once daily for a total of 12 to 18 months, then tapered or discontinued if TSH is normal at that time (Bahn 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Iodine-induced thyrotoxicosis:</b> Oral: 20 to 40 mg/day given either once or twice daily (Bahn 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Thyrotoxic crisis:</b> Oral: <b>Note:</b> Recommendations vary; use in combination with other specific agents. Dosages of 20 to 25 mg every 6 hours have been used; once stable, dosing frequency may be reduced to once or twice daily (Nayak 2006). The American Thyroid Association and the American Association of Clinical Endocrinologists recommend 60 to 80 mg/day (Bahn 2011). Rectal administration has also been described (Nabil 1982).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194291\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tapazole: 5 mg, 10 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194276\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060274\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May administer without regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132856\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and preparation in a controlled device or use of ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator) for compounding; if not prepared in a controlled device, respiratory and eye/face protection are recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194310\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at  15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060273\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of hyperthyroidism, including amelioration of hyperthyroid symptoms, prior to thyroidectomy or radioactive iodine therapy [FDA approved in pediatric patients (age not specified) and adults]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194356\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MethIMAzole may be confused with metOLazone</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194354\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema, hypersensitivity angiitis (including ANCA-positive), periarteritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Drowsiness, headache, neuritis, paresthesia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, exfoliative dermatitis, pruritus, skin pigmentation, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Goiter, hypoglycemic coma, insulin autoimmune syndrome, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Ageusia, constipation, enlargement of salivary glands, epigastric distress, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, granulocytopenia, hypoprothrombinemia, leukopenia, lymphadenopathy, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic necrosis, hepatitis, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, lupus-like syndrome, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Nephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194296\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to methimazole or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194280\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding:  May cause hypoprothrombinemia and bleeding. Monitoring is recommended, especially before surgical procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: May cause significant bone marrow depression; the most severe manifestation is agranulocytosis. Aplastic anemia, thrombocytopenia, and leukopenia may also occur. Use with caution with concomitant use of other drugs known to cause myelosuppression (particularly agranulocytosis). Monitor patients closely; discontinue if significant bone marrow suppression occurs, particularly agranulocytosis or aplastic anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dermatitis: Antithyroid agents have been associated with rare but severe dermatologic reactions. Discontinue in the presence of exfoliative dermatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fever: Discontinue in the presence of unexplained fever.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Hepatotoxicity (including acute liver failure)  may occur. Symptoms suggestive of hepatic dysfunction (eg, anorexia, pruritus, right upper quadrant pain) should prompt evaluation. Discontinue in the presence of hepatitis and clinically significant hepatic abnormality, including transaminase &gt;3 times upper limit of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypothyroidism: May cause hypothyroidism; routinely monitor TSH and free T<sub>4</sub> levels, adjust dose to maintain euthyroid state.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lupus-like syndrome:  A lupus-like syndrome may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vasculitis: ANCA-positive vasculitis may develop during therapy; discontinue use in the presence of vasculitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194344\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2A6 (weak), CYP2C9 (weak), CYP2E1 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194285\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12592&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PrednisoLONE (Systemic): MethIMAzole may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194287\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194299\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Methimazole crosses the placenta. Birth defects have been observed in neonates exposed to maternal methimazole in the first trimester of pregnancy and include anomalies of the upper gastrointestinal tract (esophageal atresia or tracheoesophageal fistula), respiratory tract (choanal atresia), skin (aplasia cutis), and facial dysmorphism. Additional abdominal wall defects (umbilicocele), ventricular septal defects, and defects of the eye and urinary system have also been reported (Alexander 2017). Hypothyroidism may occur in the newborn.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled maternal hyperthyroidism may result in adverse neonatal and maternal outcomes. Antithyroid drugs are the treatment of choice for the control of hyperthyroidism during pregnancy, although recommendations for specific agents vary by guideline (ACOG 2015; Alexander 2017; De Groot 2012). Dose requirements of methimazole may be decreased as pregnancy progresses. To prevent adverse pregnancy outcomes, maternal TT4/FT4 should be at or just above the pregnancy specific upper limit of normal (Alexander 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060270\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs of hyperthyroidism or hypothyroidism, CBC with differential, liver function (baseline and as needed); free T<sub>4</sub>, T<sub>3</sub>, serum thyroxine, free thyroxine index, prothrombin time (especially before surgical procedures)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194279\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits the synthesis of thyroid hormones by blocking the oxidation of iodine in the thyroid gland; blocks synthesis of thyroxine and triiodothyronine (T<sub>3</sub>); does not inactivate circulating T<sub>4</sub> and T<sub>3</sub></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194295\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Antithyroid: 12 to 18 hours (Clark 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 36 to 72 hours (Clark  2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Almost complete (Clark  2006) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Concentrated in thyroid gland</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: None (Cooper 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~93% (Clark 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 4 to 6 hours (Clark  2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1 to 2 hours (Clark 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10263662\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">Suppositories can be made from methimazole tablets; dissolve 1200 mg methimazole in 12 mL of water and add to 52 mL cocoa butter containing 2 drops of Span 80. Stir the resulting mixture to form a water-oil emulsion and pour into 2.6 mL suppository molds to cool.</p>\n    <div class=\"reference\">Nabil N, Miner DJ, and Amatruda JM, &quot;Methimazole: An Alternative Route of Administration,&quot; <i>J Clin Endo Metab</i>, 1982, 54(1):180-1.<span class=\"pubmed-id\">7054215</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194298\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (MethIMAzole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $44.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $76.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tapazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $245.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $424.16</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038676\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Athyrazol (HR);</li>\n      <li>Based (TW);</li>\n      <li>Danantizol (AR, PY);</li>\n      <li>Favistan (AT, CZ, DE, HR, HU, PY);</li>\n      <li>Mercaptizol (IL);</li>\n      <li>Methimazol (PL);</li>\n      <li>Methizol (DE);</li>\n      <li>Metibasol (PT);</li>\n      <li>Metizol (PL);</li>\n      <li>Metothyrin (HU);</li>\n      <li>Strumazol (BE, LU, NL);</li>\n      <li>Tapazol (BR, CO, PE, VE);</li>\n      <li>Tapazole (BB, CH, IT, LB, PH, TH);</li>\n      <li>Tapdin (PH);</li>\n      <li>Tapel (LK);</li>\n      <li>Thacapzol (SE);</li>\n      <li>Thiamazol Henning (AT, DE);</li>\n      <li>Thycaprol (DK);</li>\n      <li>Thyrozol (BG, CL, DE, LU, PL, VN);</li>\n      <li>Timazol (TH);</li>\n      <li>Tirodril (ES)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abe Y, Sato H, Sakai H et al. Antithyroid treatment of maternal hyperthyroidism during lactation. 11th International Thyroid Congress. Toronto, Ontario, Canada, September 10-15, 1995. Abstracts. <i>Thyroid</i>. 1995;5(Suppl 1):S1-275.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/7580275/pubmed\" target=\"_blank\" id=\"7580275\">7580275</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. <i>Thyroid</i>. 2017;27(3):315-389.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/28056690/pubmed\" target=\"_blank\" id=\"28056690\">28056690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, &quot;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001). Thyroid Disease in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2002, 100(2):387-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/12166417/pubmed\" target=\"_blank\" id=\"12166417\">12166417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 148: Thyroid disease in pregnancy. <i>Obstet Gynecol.</i> 2015;125(4):996-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/25798985/pubmed\" target=\"_blank\" id=\"25798985\">25798985</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bahn RS (Chair), Burch HB, Cooper DS, et al, &quot;Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,&quot; <i>Thyroid</i>, 2011, 21(6):593-646.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/21510801/pubmed\" target=\"_blank\" id=\"21510801\">21510801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark SM, Saade GR, Snodgrass WR, et al, &quot;Pharmacokinetics and Pharmacotherapy of Thionamides in Pregnancy,&quot; <i>Ther Drug Monit</i>, 2006, 28(4):477-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/16885714/pubmed\" target=\"_blank\" id=\"16885714\">16885714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper DS, &quot;Antithyroid Drugs,&quot; <i>N Engl J Med</i>, 2005, 352(9):905-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/15745981/pubmed\" target=\"_blank\" id=\"15745981\">15745981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Groot L, Abalovich M, Alexander EK, et al, &ldquo;Management of Thyroid Dysfunction During Pregnancy and Postpartum: An Endocrine Society Clinical Practice Guideline,&rdquo; <i>J Clin Endocrinol Metab</i>, 2012, 97(8):2543-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/22869843/pubmed\" target=\"_blank\" id=\"22869843\">22869843</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diav-Citrin O and Ornoy A, &quot;Teratogen Update: Antithyroid Drugs-Methimazole, Carbimazole, and Propylthiouracil,&quot; <i>Teratology</i>, 2002, 65(1):38-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/11835230/pubmed\" target=\"_blank\" id=\"11835230\">11835230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Methimazole tablet [prescribing information]. Princeton, NJ: Sandoz Inc; August 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nabil N, Miner DJ, and Amatruda JM, &quot;Methimazole: An Alternative Route of Administration,&quot; <i>J Clin Endocrinol Metab</i>, 1982, 54(1):180-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/7054215/pubmed\" target=\"_blank\" id=\"7054215\">7054215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nayak B and Burman K, &quot;Thyrotoxicosis and Thyroid Storm,&quot; <i>Endocrinol Metab Clin North Am</i>, 2006, 35(4):663-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/17127140/pubmed\" target=\"_blank\" id=\"17127140\">17127140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/27521067/pubmed\" target=\"_blank\" id=\"27521067\">27521067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Canada: Elsevier; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stagnaro-Green A, Abalovich M, Alexander E, et al, &quot;Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum,&quot; <i>Thyroid</i>, 2011, 21(10):1081-125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-pediatric-drug-information/abstract-text/21787128/pubmed\" target=\"_blank\" id=\"21787128\">21787128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tapazole tablet (methimazole) [prescribing information]. Bristol, TN: King Pharmaceuticals, Inc; July 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12592 Version 131.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24520218\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F194315\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060271\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F13766154\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060265\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F194291\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F194276\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060274\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132856\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F194310\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060273\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F194356\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F194354\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F194296\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F194280\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F194344\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F194285\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F194287\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F194299\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060270\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F194279\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F194295\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10263662\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F194298\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038676\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12592|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=methimazole-drug-information\" class=\"drug drug_general\">Methimazole: Drug information</a></li><li><a href=\"topic.htm?path=methimazole-patient-drug-information\" class=\"drug drug_patient\">Methimazole: Patient drug information</a></li></ul></div></div>","javascript":null}